Company news
Caprock Mining Corp (CSE:CAPR) news
Every Caprock Mining Corp press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases — page 2
Caprock Mining Announces Plans to Commence Drill Program Designed for Pit-Constrained Mineral Resource Expansion at Destiny
April 22, 2026
Caprock Mining Intersects 38.48 g/t Au over 1.6m Included Within a Broader Interval of 2.84 g/t over 23.2m at Destiny
March 25, 2026
Early Warning Press Release - Frank Guillemette Announces Completion of Acquisition of Common Shares of Caprock Mining Corp.
March 23, 2026
Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
March 12, 2026
Capricor Therapeutics Announces Late-Breaking HOPE-3 Data at the 2026 MDA Conference Demonstrating Significant Functional Benefits of Deramiocel for Duchenne Muscular Dystrophy
March 12, 2026
Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA
March 10, 2026
Capricor Therapeutics to Present Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Update on March 12
March 9, 2026
Caprock Announces High-Grade Assay Results and Validation of Structural Geologocal Model at Destiny
February 25, 2026
Capricor Therapeutics Announces Late-Breaking Presentation at 2026 MDA Clinical and Scientific Conference
February 24, 2026
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Atkore Inc. (ATKR), Axsome Therapeutics, Inc. (AXSM), Capricor Therapeutics, Inc. (CAPR), and CTO Realty Growth, Inc. (CTO)
February 5, 2026
Big Ridge Gold Corp Provides Corporate Update
January 21, 2026
Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA Following FDA Review of HOPE-3 Topline Data
January 20, 2026
Caprock Provides Update on Drilling and Announces Expansion of Drill Program at Its Destiny Gold Project
December 17, 2025
Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar Highlighting Positive Phase 3 HOPE-3 Topline Results in Duchenne Muscular Dystrophy
December 16, 2025
Caprock Announces Closing of Private Placement and Confirmation of Payment of Anniversary Payment on Destiny Option
December 12, 2025
Capricor Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock
December 5, 2025
Caprock Announces Proposed Private Placement
December 4, 2025
Capricor Therapeutics Announces Proposed Public Offering of Common Stock
December 4, 2025
Capricor Therapeutics Announces Positive Topline Results from Pivotal Phase 3 HOPE-3 Study of Deramiocel in Duchenne Muscular Dystrophy
December 3, 2025
Capricor Therapeutics Presents New Data Demonstrating a Scalable Framework for Loading Therapeutic Oligonucleotides into Exosomes at AAEV 2025
November 24, 2025
Caprock Announces Commencement of Drill Program at Destiny
November 11, 2025
Capricor Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 10, 2025
Kuehn Law Encourages Investors of Capricor Therapeutics, Inc. to Contact Law Firm
November 10, 2025
Caprock Announces Option and RSU Grant
November 5, 2025
Capricor Therapeutics, Inc. Long-Term Shareholder Announcement: Johnson Fistel Encourages Investors to Reach Out For More Information About Continuing Investigation
November 4, 2025
Capricor Therapeutics Publishes Peer-Reviewed Study in Biomedicines Describing the Mechanism of Action and Potency Assay for its Investigational Cell Therapy, Deramiocel
November 3, 2025
Capricor Therapeutics to Present Third Quarter 2025 Financial Results and Recent Corporate Update on November 10
October 31, 2025
Caprock Announces Receipt of Permit and Plans for Commencement of Drill Program at Destiny
October 31, 2025
Caprock Announces Changes to Its Board of Directors
October 23, 2025
CAPRICOR INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into Capricor Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
October 8, 2025
Caprock Announces Closing of Private Placement and Debt Settlement and Provides Early Warning Disclosure
October 6, 2025
Capricor Therapeutics Provides Regulatory Update on Deramiocel Program for Duchenne Muscular Dystrophy Following Type A Meeting
September 25, 2025
CAPRICOR ALERT: Bragar Eagel & Squire, P.C. is Investigating Capricor Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
September 16, 2025
CAPR Deadline: CAPR Investors with Losses in Excess of $100K Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit
September 15, 2025
CAPR DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important September 15 Deadline in Securities Class Action - CAPR
September 15, 2025
Shareholders of Capricor Therapeutics, Inc. Should Contact The Gross Law Firm Before September 15, 2025 to Discuss Your Rights - CAPR
September 15, 2025
FINAL DEADLINE ALERT: Faruqi & Faruqi Reminds Capricor Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 15, 2025 - CAPR
September 15, 2025
Lost Money on Capricor Therapeutics, Inc. (CAPR)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
September 15, 2025
Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before September 15, 2025 to Discuss Your Rights - CAPR
September 15, 2025
Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR
September 15, 2025
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
September 15, 2025
CAPR DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important September 15 Deadline in Securities Class Action - CAPR
September 14, 2025
CAPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
September 14, 2025
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
September 14, 2025
CAPR IMPORTANT DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important September 15 Deadline in Securities Class Action - CAPR
September 14, 2025
CAPRICOR DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors in Capricor Therapeutics, Inc. of the September 15th Deadline for the Class Action Lawsuit
September 14, 2025
CAPR IMPORTANT DEADLINE: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important September 15 Deadline in Securities Class Action - CAPR
September 13, 2025
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics
September 13, 2025
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
September 13, 2025
CAPR IMPORTANT DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important September 15 Deadline in Securities Class Action - CAPR
September 12, 2025